Tagtociclib (hydrate)

• Description:

  PF-07104091 hydrate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E1-amplified cancers. (patent WO2020157652A2) .

• Product Name Alternative:

  PF-07104091 (hydrate)

• UNSPSC:

  12352005

• Target:

  CDK; GSK-3

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pf-07104091-hydrate.html

• Purity:

  99.73

• Solubility:

  DMSO : 116.67 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(COC)=NN1C)NC2=NNC([C@](CC3)([H])C[C@@H]3OC(NC(C)C)=O)=C2.[H]O[H]

• Molecular Formula:

  C19H30N6O5

• Molecular Weight:

  422.48

• References & Citations:

  [1]Douglas Carl BEHENNA, et al. Cdk2 inhibitors. WO2020157652A2.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  CDK2

• CAS Number:

  [2733575-91-0]